Amlodipine / Valsartan Mylan


amlodipine / valsartan

This medicine is authorised for use in the European Union.


This is a summary of the European public assessment report (EPAR) for Amlodipine/Valsartan Mylan. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Amlodipine/Valsartan Mylan.

For practical information about using Amlodipine/Valsartan Mylan, patients should read the package leaflet or contact their doctor or pharmacist.

This EPAR was last updated on 02/02/2021

Authorisation details

Product details
Amlodipine / Valsartan Mylan
Agency product number
Active substance
  • Amlodipine besilate
  • valsartan
International non-proprietary name (INN) or common name
  • amlodipine
  • valsartan
Therapeutic area (MeSH)
Anatomical therapeutic chemical (ATC) code

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines.

Publication details
Marketing-authorisation holder
Mylan S.A.S
Date of issue of marketing authorisation valid throughout the European Union
Contact address
117 Allée des Parcs
69800 Saint Priest

Product information

14/01/2021 Amlodipine / Valsartan Mylan - EMEA/H/C/004037 - R/0008


Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Agents acting on the renin-angiotensin system

Therapeutic indication

Treatment of essential hypertension.

Amlodipine/Valsartan Mylan is indicated in adults whose blood pressure is not adequately controlled on amlodipine or valsartan monotherapy.

Assessment history

Changes since initial authorisation of medicine

Related content

How useful was this page?

Add your rating
1 rating